Business Context and Reporting Period
This Form 8-K Current Report from Biocardia, Inc. covers events occurring on December 2, 2025. The filing primarily addresses corporate governance changes, specifically the appointment of a new director and the conclusion of a prior director's term, alongside the results of the Company's Annual Meeting of Shareholders held on the same date.
Key Financial Metrics
This filing is a current report regarding corporate events and does not contain financial statements. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes and Corporate Actions
Board of Directors Changes
- Appointment: Marvin Slosman was appointed as a member of the Board of Directors, effective December 2, 2025. His term expires at the 2028 Annual Meeting. He has been designated as an independent director and appointed to the Audit Committee.
- Departure: Dr. Richard Krasno completed his term on the Board of Directors on December 2, 2025. His departure was not due to any disagreement with the Company regarding operations, policies, or practices.
Annual Meeting Results
Holders of 5,913,667 shares (55.72% of voting power) attended the Annual Meeting, constituting a quorum. The following proposals were approved:
- Proposal 1 (Election of Directors): Marvin Slosman, Jay M. Moyes, and Simon H. Stertzer, M.D. were elected as Class III directors.
- Proposal 2 (Equity Incentive Plan): Shareholders approved an amendment to the 2016 Equity Incentive Plan to extend its term to October 31, 2035, and modify the automatic share reserve increase mechanism to 4.0% of outstanding shares annually.
- Proposal 3 (Auditor Ratification): The appointment of PKF San Diego, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.
- Proposal 4 (Executive Compensation): Executive compensation was approved on an advisory basis.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, forward-looking outlooks, or specific risk factors beyond standard corporate governance disclosures. The appointment of Mr. Slosman, who serves as CEO of InspireMD, Inc., suggests a strategic focus on leveraging experience in vascular and carotid artery disease management solutions.
Investor Verification Checklist
- Verify the specific terms of the amended 2016 Equity Incentive Plan, particularly the 4.0% annual share reserve increase and the 2035 expiration date.
- Review the 2025 Proxy Statement for details on the Non-Employee Director Compensation Policy applicable to the new director, Marvin Slosman.
- Confirm the independence status and background of the newly elected directors as disclosed in the proxy materials.
- Monitor future filings for the Company's audited financial results for the fiscal year ending December 31, 2025, as the auditor (PKF San Diego, LLP) has been ratified.